375 related articles for article (PubMed ID: 24352344)
21. Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database.
Mali G; Ahuja V; Dubey K
J Clin Pharm Ther; 2021 Feb; 46(1):99-105. PubMed ID: 32926446
[TBL] [Abstract][Full Text] [Related]
22. The safety of incretin-based therapies--review of the scientific evidence.
Drucker DJ; Sherman SI; Bergenstal RM; Buse JB
J Clin Endocrinol Metab; 2011 Jul; 96(7):2027-31. PubMed ID: 21734003
[TBL] [Abstract][Full Text] [Related]
23. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
24. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.
Wilhite K; Reid JM; Lane M
Ann Pharmacother; 2024 Jul; 58(7):685-689. PubMed ID: 37881914
[TBL] [Abstract][Full Text] [Related]
25. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Abd El Aziz M; Cahyadi O; Meier JJ; Schmidt WE; Nauck MA
Diabetes Obes Metab; 2020 Apr; 22(4):699-704. PubMed ID: 31750601
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
Neumiller JJ
Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
[TBL] [Abstract][Full Text] [Related]
27. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
Dejager S; Schweizer A
Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
[TBL] [Abstract][Full Text] [Related]
28. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
29. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
[TBL] [Abstract][Full Text] [Related]
30. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Pratley RE
Medscape J Med; 2008 Jul; 10(7):171. PubMed ID: 18769687
[TBL] [Abstract][Full Text] [Related]
31. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
32. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
33. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
Garber AJ
J Am Osteopath Assoc; 2011 Jul; 111(7 Suppl 5):S20-30. PubMed ID: 21813733
[TBL] [Abstract][Full Text] [Related]
34. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603
[TBL] [Abstract][Full Text] [Related]
35. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Diabetes Obes Metab; 2014 Jan; 16(1):48-56. PubMed ID: 23837679
[TBL] [Abstract][Full Text] [Related]
36. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Viereck C; Boudes P
Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
[TBL] [Abstract][Full Text] [Related]
37. Liraglutide: effects beyond glycaemic control in diabetes treatment.
McGill JB
Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
[TBL] [Abstract][Full Text] [Related]
38. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
Drab SR
Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
[TBL] [Abstract][Full Text] [Related]
39. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
40. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
